Phase 2 study

Not yet recruiting Phase 2

Sources: ClinicalTrials.gov Checked: 11 October 2026 Not medical advice

This trial at a glance

Status Not yet recruiting
Phase Phase 2
Sponsor VelaVigo Bio Inc
Registry number NCT07772934
Started 24 August 2026 Today 16 October 2026 Estimated completion 27 February 2029

Where this trial is running

Trial sites and the status recorded for each
SiteCityState or countryStatus at this site
Macquarie University Randwick NSW Status not stated
Scientia Clinical Research Randwick NSW Status not stated
Cancer Care Wollongong Wollongong NSW Status not stated
Peninsula and South Eastern Haematology and Oncology Group Frankston VIC Status not stated

voxsanity.com.au · trial sites from public registries · registry record synced 11 October 2026 · not medical advice

Who can join

Age 18 Years and over
Sex Anyone, regardless of sex
Healthy volunteers Not accepted
Enrolment target 260

The official eligibility criteria

Registry text, reproduced exactly. These are the words the trial's sponsor published on ClinicalTrials.gov. They have not been edited, shortened or rewritten, and they are written for researchers rather than for patients.

Inclusion Criteria:

1. The participant or the participant's legally acceptable representative is willing and able to provide a written ICF before initiating any trial procedure.

2. Histologically or cytologically confirmed unresectable advanced/metastatic solid tumor .

3. At least one measurable lesion as assessed by the investigator according to RECIST v1.1 criteria.

4. Male or female adults (defined as ≥ 18 years of age).

5. ECOG performance status 0-1.

6. Life expectancy greater than 12 weeks.

7. Archived tumor tissue sample available or able to undergo a fresh biopsy collection.

8. Adequate organ and bone marrow function.

Exclusion Criteria:

1. Any unresolved toxicity of Grade ≥2 from previous anti-cancer treatment.

2. Known or suspected brain metastases, or spinal cord compression.

3. Prior treatment with an ADC targeting EGFR x CDH17 bispecific ADC.

4. Prior treatment with any ADC carrying a topoisomerase I inhibitor (TOP1i) payload.

5. Has a medical history of interstitial lung diseases or current interstitial lung diseases or who are suspected to have these diseases by imaging at screening.

Dates on the record

Started 24 August 2026
Estimated completion 27 February 2029
Registry last updated 22 September 2026
Checked by Voxsanity 11 October 2026

Results, publications and the official record

Sources and dates

  • ClinicalTrials.gov – the record this page reformats
  • ClinicalTrials.gov processing date: 22 September 2026.
  • This page last checked by Voxsanity: 11 October 2026.

Voxsanity reformats data from public registries into this layout. It does not edit, interpret or add to what the registry published.

Not medical advice.

Individual trial records are refreshed on a rolling basis rather than all at once, so a record may be up to several weeks old. Each trial page and trial card shows the date its own record was last synced. Where a record has lagged, its status, sites and enrolment can differ from the current registry state in either direction, so check the registry link on the trial page before acting on them.

Letter for your doctor

A one-page summary of this trial to print or email to your GP. It carries the registry's own record of the trial and its eligibility criteria, and nothing Voxsanity has written about whether it suits you.